Magical Trade
Monday, June 27, 2022
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Magical Trade
No Result
View All Result
Home Trade News

Peter Thiel-backed psychedelic start-up increases stake in Compass Pathways

by
November 29, 2021
in Trade News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Man in custody after Rudy Giuliani was ‘slapped’ in the back, police say

Fund manager names one trend that will ‘affect all industries’ — and reveals how he’s trading it

Atai Life Sciences at the Nasdaq for its IPO, June 18, 2021.

Source: Nasdaq

Atai Life Sciences, the Peter Thiel-backed start-up that wants to use psychedelic drugs to treat mental health conditions, has increased its stake in fellow drug developer Compass Pathways.

Atai bought another 420,000 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%.

The new shares were bought at around $31 each and Atai paid around $12 million in total.

Atai, which is already the largest Compass Pathways shareholder, is planning to increase its stake in Compass Pathways to more like 29% in the coming weeks, according to a source close to the companies who preferred to remain anonymous as the discussions are private.

Christian Angermayer, the founder and chairman of Atai, told CNBC Monday that he believes Compass Pathways is one of the most undervalued and impactful biotech stocks.

Compass Pathways, which Thiel has also invested in, wants to use psilocybin (the compound found in magic mushrooms) to treat depression. It debuted on the Nasdaq stock exchange last September and it has a current market value of $1.4 billion.

Meanwhile, Atai listed on the Nasdaq in June, raising $225 million at a valuation of $2.3 billion. The stock immediately popped 40% but it has since halved in value and Atai’s current market cap is $1.7 billion.

Billionaire Peter Thiel, PayPal co-founder and chairman of Palantir Technologies, during a news conference in Tokyo, Japan, on Nov. 18, 2019.

Kiyoshi Ota/Bloomberg via Getty Images

Atai, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.

There is growing interest in certain psychedelics after recent clinical studies suggested that some could help patients with a number of mental illnesses, either in combination with traditional solutions or in cases where nothing else has worked.

“The current treatments [for mental health issues] which are out there are definitely not sufficient,” company co-founder Angermayer told CNBC in a previous interview.

“I don’t want to say they don’t work at all because some people are helped by them, but they’re not sufficient.”

Almost a billion people suffer from mental health problems worldwide, according to the World Health Organization.

ShareTweetPin

Related Posts

Man in custody after Rudy Giuliani was ‘slapped’ in the back, police say

by
June 27, 2022
0

A man was taken into custody Sunday after he was alleged to have slapped former New York Mayor Rudy Giuliani...

Fund manager names one trend that will ‘affect all industries’ — and reveals how he’s trading it

by
June 27, 2022
0

For decades, globalization has been an established part of the global economic system, but fund manager Dan Katz believes its...

These global stocks look oversold — and analysts are expecting a rebound

by
June 27, 2022
0

Market watchers have been reluctant to call the bottom on the sell-off in global stocks this year, but some assets...

Asia-Pacific markets gain as investors monitor recession fears

by
June 27, 2022
0

A man walks past the Tokyo Stock Exchange (TSE), operated by Japan Exchange Group Inc. (JPX), in Tokyo, Japan, on...

Russia Defaults on Foreign Debt for First Time Since 1918

by
June 27, 2022
0

Associated Press EXPLAINER: What's the impact of a Russian debt default? Russia is poised to default on its foreign debt...

Next Post

Here's what Wall Street's major banks are saying about omicron's potential market impact

UK stockbroker AJ Bell takes on fintech rivals with commission-free investing app

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • Fund manager believes FAANG is dead — says now it’s all about MANTA

    0 shares
    Share 0 Tweet 0
  • Bank of America names its top global tech stocks — including one it says has upside of 100%

    0 shares
    Share 0 Tweet 0
  • ‘Conviction sell’: UBS says avoid these global stocks amid rising headwinds

    0 shares
    Share 0 Tweet 0
  • These are the global stocks to own if stagflation hits, according to Credit Suisse

    0 shares
    Share 0 Tweet 0
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.magicaltrade.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.magicaltrade.net